3:23 PM
 | 
Nov 01, 2018
 |  BC Extra  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma.

On the CAR T front, bluebird bio Inc. (NASDAQ:BLUE) reported data from seven evaluable patients in the Phase I CRB-402 trial to treat relapsed or refractory MM following at least three prior regimens showing that its bb21217 led to a response rate of 85% per International Myeloma Working Group (IMWG) criteria. The responses included one stringent complete response (CR), three very good partial responses (VGPRs) and two PRs.

bb21217 is the company's next-generation lentiviral CAR T therapy targeting BCMA. bluebird added $15.45 (13%) to $130.15 on Thursday.

The Juno Therapeutics Inc. subsidiary of Celgene Corp. (NASDAQ:CELG) reported the first data for...

Read the full 656 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >